Clinical trial
Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute…
NCT00443209 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00443209 |
|---|---|
| Title | Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012) |
| Official title | A Multicenter, Double-Blind, Active-Controlled, Parallel Group Study to Examine the Safety, Tolerability and Efficacy of Oral MK-0974 for the Long Term Treatment of Acute Migraine With or Without Aura |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Migraine |
| Intervention type | Drug |
| Interventions | Telcagepant 300 mg soft gel capsules, Telcagepant 280 mg tablets, Rizatriptan 10 mg tablets, Placebo to telcagepant capsules, Placebo to telcagepant tablets, Placebo to rizatriptan tablets |
| Enrollment | 1,068 |
| Start date | Feb 21, 2007 |
| Primary completion | Jan 22, 2009 |
| Completion | Jan 22, 2009 |
| First posted | Mar 5, 2007 |
| Last update posted | Oct 17, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: